EP3773725A1 — Treatment of trk-associated cancers
Assigned to Loxo Oncology Inc · Expires 2021-02-17 · 5y expired
What this patent protects
Provided herein are compounds and pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of cancer. More particularly, provided herein are method of treating cancer (e.g., a Trk-associated cancer) by administration of one or more Trk in…
USPTO Abstract
Provided herein are compounds and pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of cancer. More particularly, provided herein are method of treating cancer (e.g., a Trk-associated cancer) by administration of one or more Trk inhibitors and optionally an immunotherapy agent.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.